On May 22, 2025 Foundation Medicine, Inc., a genomic company committed to transforming cancer care, reported that the company and its collaborators will present more than 15 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from May 30 to June 3 in Chicago (Press release, Foundation Medicine, MAY 22, 2025, View Source [SID1234653345]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Foundation Medicine’s research presented at the meeting will include new insights across breast cancer, lung cancer and prostate cancer, including an oral presentation highlighting the findings from the COMRADE phase 2 clinical trial in castration resistant prostate cancer, which leveraged the research use version of FoundationOneMonitor, the company’s tissue-free treatment response monitoring assay, for serial ctDNA analysis. (Abstract 5007, Tuesday, June 3, at 11:57 am – 12:09 pm CT, Hall D1)
"In partnership with over 30 clinical collaborators, Foundation Medicine’s new research at the ASCO (Free ASCO Whitepaper) Annual Meeting further reinforces the important role high-quality biomarker testing plays in delivering personalized cancer care," said Mia Levy, M.D., Ph.D., chief medical officer at Foundation Medicine. "From exploring the role of innovative and complex biomarkers to expanding the clinical utility of genomic profiling, we are excited to demonstrate how our testing portfolio, including our new treatment response monitoring assay, can help providers make more informed treatment decisions for their patients."
To access the abstracts being presented at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting, please visit ASCO (Free ASCO Whitepaper).org/abstracts.
Follow Foundation Medicine on LinkedIn, X and Instagram for more updates from #ASCO25 and visit us in person at booth #27021.
Complete list of Foundation Medicine’s abstracts at the 2025 ASCO (Free ASCO Whitepaper) Annual Meeting
Abstract Number
Title
Product
Saturday, May 31
3570
Comparison of MET genomic alterations (GA) identified in colorectal cancer (CRC) vs gastric cancer (GCA)
FoundationOneCDx
4153
Pancreatic adenosquamous carcinoma (PASC): A comparative genomic landscape study
FoundationOneCDx
4183
BRCA1/2 and PALB2 short variants (SVs) contributed by clonal hematopoiesis (CH) in liquid biopsies (LBx) from patients with advanced pancreatic cancer (PC)
FoundationOneCDx / FoundationOneLiquid CDx
8036
Tumor type prediction via tissue- and liquid-based comprehensive genomic profiling: High-specificity tobacco signature detection to support lung cancer diagnosis
FoundationOneCDx / FoundationOneLiquid CDx
8039
Clinical utility of pathologist-directed comprehensive comparative molecular profiling for the classification of separate primary lung cancers vs. intrapulmonary metastasis
FoundationOneCDx
8628
Association of circulating tumor DNA (ctDNA) variant allelic frequency (VAF) with outcomes on matched targeted therapies (TT) in advanced non-small cell lung cancer (aNSCLC)
FoundationOneLiquid CDx
11161
Real-world analysis of factors influencing turnaround time (TAT) for tissue comprehensive genomic profiling (CGP) in non-small cell lung cancer (NSCLC)
FoundationOneCDx
Sunday, June 1
5592
Distinguishing tumor vs. clonal hematopoiesis (CH)–derived TP53 and BRCA1/2 alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making
FoundationOneCDx / FoundationOneLiquid CDx
6528
Nucleophosmin (NPM1) genomic alterations (GA) in acute myeloid leukemia (AML): A genomic landscape study
FoundationOneHeme
9520
Homologous recombination deficiency signature (HRDsig) in advanced cutaneous melanoma (ACM): A genomic landscape study
FoundationOneCDx
Monday, June 2
1043
TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer
FoundationOneCDx
1048
Genomic alterations (GAs) associated with durability of benefit from trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1) and sacituzumab govitecan (SG) in metastatic breast cancer (MBC)
FoundationOneCDx / FoundationOneLiquid CDx
1065
Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation-negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer
FoundationOneCDx / FoundationOneLiquid CDx
3081
Genomic landscape of 5’methylthioadenosine phosphorylase (MTAP) deleted (MTAP loss) non-squamous carcinoma of unknown primary site (nsCUP)
FoundationOneCDx
5064
Additive clinical utility of tissue biomarkers of microsatellite instability (MSI) status and tumor mutational burden (TMB) to predict immune checkpoint inhibitor (ICI) effectiveness for real-world patients with metastatic castration-resistant prostate cancer (mCRPC)
FoundationOneCDx
4564
Fibroblast growth factor receptor 3 (FGFR3) alteration status and outcomes with immune checkpoint inhibitors (ICPI) in patients with metastatic urothelial carcinoma
FoundationOneCDx
Tuesday, June 3
5007
A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis
Research use version of FoundationOneMonitor*